800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

view all Clinical Trials

Overview

The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.

Clinical Trial Information

Protocol

TIRB# 30641

Phase

1

Condition(s)

Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF)

Investigator

Gerard Criner, MD

Coordinator

Debasree Sana Boral

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Full Title

Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect

Related Clinical Trials

A Study of Mosliciguat in PH-ILD (PHocus)

TIRB#: 32203
  • Conditions: Interstitial Lung Disease (ILD), Pulmonary Hypertension (PH), Pulmonary Vascular Disease
  • Investigator: Parth Rali, MD
  • Coordinator: Kim Selwood
View Details

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

TIRB#: 32025
  • Conditions: Interstitial Lung Disease (ILD), Pulmonary Fibrosis (Including IPF)
  • Investigator: Parth Rali, MD
  • Coordinator: Kim Selwood
View Details

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

TIRB#: 31970
  • Conditions: Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF)
  • Investigator: Gerard Criner, MD
  • Coordinator: Kriti Mittal, Elaina Budny, Rachel Nwafo
View Details